Drug Development

Novel Immunoliposome Provides a Targetable Drug Delivery Vehicle

Published in Gene Therapy Weekly, May 8th, 1995

Novel immunoliposome combines a superior drug delivery vehicle with specific in vivo targeting efficiency, reported researchers recently.

Previous research has shown that while immunoliposomes are effective in specific binding to target cells in vitro, their in vivo targeting efficiency is relatively low. Researchers have determined that highly efficient target binding and a relatively low level of reticuloendothelial system (RES) uptake of the immunoliposomes are mutually exclusive.

Kazuo Maruyama et al., working together from three different institutions, have developed a liposome modified with amphipathic poly(ethylene glycol)s (PEG) which...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1995-05-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry